Advertisement

CNS Drugs

, Volume 20, Issue 5, pp 419–426 | Cite as

Zolpidem Extended-Release

Adis Drug Profile

Abstract

▲ Zolpidem extended-release, or controlled-release (CR), is a new formulation of zolpidem, a nonbenzodiazepine hypnotic. It is indicated in the US for the treatment of insomnia, characterised by difficulties with sleep onset and/or sleep maintenance. Zolpidem CR is a dual-layered tablet; one layer releases zolpidem immediately and a second layer provides a slower release of additional zolpidem for maintenance of plasma zolpidem concentrations.

▲ Efficacy of zolpidem CR was assessed in two 3-week, randomised, double-blind, placebo-controlled, phase III polysomnography trials in younger adult (aged 18–64 years) or elderly (aged ≥65 years) patients with primary insomnia. Patients received nightly zolpidem CR (12.5mg in younger adult and 6.25mg in elderly patients). Efficacy was assessed objectively on nights 1, 2, 15 and 16. Patients who received zolpidem CR had significantly improved objective latency to persistent sleep, wake time after sleep onset and sleep efficiency on assessment nights compared with placebo recipients.

▲ In subjective assessments of sleep quality on day 2 and nights 15 and 22, significantly more zolpidem CR than placebo recipients gave favourable responses on a Patient Global Impression scale in the study in younger adult patients. In the other study, significantly more elderly patients in the zolpidem CR group rated their sleep as improved compared with the placebo group.

▲ Zolpidem CR was generally well tolerated and appears to have a tolerability profile similar to that of the original formulation of zolpidem.

Keywords

Placebo Recipient Zolpidem Sleep Onset Sleep Efficiency Flurazepam 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. 1.
    National Institutes of Health. National Institutes of Health state of the science conference statement: manifestations and management of chronic insomnia in adults June 13–15, 2005. Sleep 2005 Sep 1; 28(9): 1049–57Google Scholar
  2. 2.
    Walsh JK. Clinical and socioeconomic correlates of insomnia. J Clin Psychiatry 2004; 65 Suppl. 8: 13–9PubMedGoogle Scholar
  3. 3.
    Sanofi-Synthelabo Inc. Ambien® (zolpidem tartrate tablets): US prescribing information [online]. Available from URL: http://www.sanofi-aventis.us/ [Accessed 2006 Mar 14]
  4. 4.
    Swainston Harrison T, Keating GM. Zolpidem: a review of its use in the management of insomnia. CNS Drugs 2005; 19(1): 65–89PubMedCrossRefGoogle Scholar
  5. 5.
    Sanofi-Synthelabo Inc. Ambien CR™ (zolpidem tartrate extended-release tablets): US prescribing information [online]. Available from URL: http://www.sanofi-aventis.us/ [Accessed 2005 Oct 14]
  6. 6.
    Holm KJ, Goa KL. Zolpidem: an update of its pharmacology, therapeutic efficacy and tolerability in the treatment of insomnia. Drugs 2000 Apr; 59(4): 865–89PubMedCrossRefGoogle Scholar
  7. 7.
    Stanley N, Hindmarch I, Legangneux E, et al. Zolpidem modified-release 12.5 mg improves measures of sleep continuity in a model of sleep disturbance (traffic noise) compared with standard zolpidem 10 mg [abstract no. 321]. Pharmacotherapy 2005; 25(10): 1504. Plus oral presentation presented at the 2005 Annual Meeting of the American College of Clinical Pharmacy; 2005 Oct 23–26; San Francisco (CA)Google Scholar
  8. 8.
    Hindmarch I, Stanley N, Legangneux E, et al. Zolpidem modified-release significantly reduces latency to persistent sleep 4 and 5 hours postdose compared with standard zolpidem in a model assessing the return to sleep following nocturnal awakening [abstract no. 0731]. Sleep 2005; 28 Suppl.: A245. Plus poster presented at the 19th Annual Meeting of the Associated Professional Sleep Societies; 2005 Jun 18–23; Denver (CO)Google Scholar
  9. 9.
    Blin O, Micallef-Rolle J, Legangneux E, et al. Zolpidem modified-release 12.5 mg has no residual effects on psychomotor performance and cognitive function in healthy adult subjects [abstract no. 0733]. Sleep 2005; 28 Suppl.: A246. Plus poster presented at the 19th Annual Meeting of the Associated Professional Sleep Societies; 2005 Jun 18–23; Denver (CO)Google Scholar
  10. 10.
    Legangneux E, Hindmarch I, Zobouyan I. Zolpidem modified-release 6.25 mg and double dose 12.5 mg have no residual effects on central nervous system integrative capacity, sensorimotor and psychomotor performance, and immediate and delayed memory recall in healthy elderly subjects [abstract no. 0729]. Sleep 2005; 28 Suppl.: A245. Plus poster presented at the 19th Annual Meeting of the Associated Professional Sleep Societies; 2005 Jun 18–23; Denver (CO)Google Scholar
  11. 11.
    Soubrane C, Walsh J, Roth T. Zolpidem modified-release improves sleep induction, sleep maintenance, sleep duration, and quality of sleep without next-day residual effects in adults with primary insomnia [abstract no. 0728]. Sleep 2005; 28 Suppl.: A244–A245. Plus poster presented at the 19th Annual Meeting of the Associated Professional Sleep Societies; 2005 Jun 18–23; Denver (CO)Google Scholar
  12. 12.
    Roehrs TA, Soubrane C, Roth T. Zolpidem modified-release objectively and subjectively improves sleep maintenance and retains the characteristics of standard zolpidem on sleep initiation and duration in elderly patients with primary insomnia [abstract no. 0725]. Sleep 2005; 28 Suppl.: A244. Plus poster presented at the 19th Annual Meeting of the Associated Professional Sleep Societies; 2005 Jun 18–23; Denver (CO)Google Scholar
  13. 13.
    Johnston GA. GABAa receptor channel pharmacology. Curr Pharm Des 2005; 11(15): 1867–85PubMedCrossRefGoogle Scholar
  14. 14.
    Data on file. Sanofi-Aventis, 2006Google Scholar
  15. 15.
    Weinling E, McDougall S, Andre F, et al. Pharmacokinetic profile of a new modified release formulation of zolpidem designed to improved sleep maintenance. Fundam Clin Pharmacol 2006, doi: 10.1111/j.l472-8206.2006.00415.xGoogle Scholar

Copyright information

© Adis Data Information BV 2006

Authors and Affiliations

  1. 1.Adis International LimitedMairangi Bay, AucklandNew Zealand

Personalised recommendations